Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats

Journal of Hepatology

Volumn 37, Issue 1, 2002, Pages 22-30

  Yoshiji, Hitoshi ^a   Yoshii, Junichi ^a   Ikenaka, Yasuhide ^a   Noguchi, Ryuichi ^a   Tsujinoue, Hirohisa ^a   Nakatani, Toshiya ^a   Imazu, Hiroo ^a   Yanase, Koji ^a   Kuriyama, Shigeki ^b   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin II; Hepatocarcinogenesis; Liver fibrosis; Renin angiotensin system

Indexed keywords

ALPHA ACTIN; AMINO ACID; CHOLINE; DIETHYLNITROSAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDROXYPROLINE; LIVER ENZYME; MESSENGER RNA; PERINDOPRIL; PROCOLLAGEN; ALKYLATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FIBROGENESIS; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER FIBROSIS; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TUMOR GROWTH; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; ENZYMOLOGY; FISCHER 344 RAT; LIVER; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; PHYSIOLOGY; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER NEOPLASMS; PRECANCEROUS CONDITIONS;

ALKYLATING AGENTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CHOLINE; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PERINDOPRIL; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; RENIN-ANGIOTENSIN SYSTEM;

EID: 0035991447     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00104-6     Document Type: Article

References (54)

1. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia
2. Biological functions of angiotensin and its receptors
3. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis
4. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites
5. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis
6. The role of vasoactive mediators in portal hypertension
7. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver
8. Cytokines and fibrogenesis
9. Angiotensin II induces contraction and proliferation of human hepatic stellate cells
10. Angiotensin II stimulates angiogenesis in the chorioallantoic membrane of the chick embryo
11. Neovascularization produced by angiotensin II
12. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells
13. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride
14. Angiogenesis in cancer, vascular, rheumatoid and other disease
15. The implications of angiogenesis for the biology and therapy of cancer metastasis
16. Clinical applications of angiogenic growth factors and their inhibitors
17. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma
18. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
19. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor
20. Activity of serum angiotensin-converting enzyme as a tumour marker of hepatocellular carcinoma
21. Angiogenesis is an early event in the development of chemically induced skin tumors
22. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
23. Angiogenesis is an early event in the generation of myc-induced lymphomas
24. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis
25. Inhibition by N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid of exogenous and endogenous development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in the livers of rats
26. Formation and metabolism of alkylated nucleosides: Possible role in carcinogenesis by nitroso compounds and alkylating agents
27. Mechanisms of carcinogenesis induced by alkylating agents
28. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats
29. Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats
30. Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, -amino acid-defined diet in rats
31. Inhibitory effect of dietary iron deficiency on inductions of putative preneoplastic lesions as well as 8-hydroxydeoxyguanosine in DNA and lipid peroxidation in the livers of rats caused by exposure to a choline-deficient L-amino acid defined diet
32. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis in rats
33. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis
34. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats
35. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet
36. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9)
37. Possible prevention of hepatocarcinogenesis with Sho-saiko-to
38. Medium-term bioassay system for detection of carcinogens and modifiers of hepatocarcinogenesis utilizing the GST-P positive liver cell focus as an endpoint marker
39. Comparative histochemical investigation of the glutathione S-transferase placental form and gamma-glutamyltranspeptidase during N-nitrosobis(2-hydroxypropyl)amine-induced pancreatic carcinogenesis in hamsters
40. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression
41. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model
42. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma
43. Hepatocellular carcinoma
44. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis
45. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy
46. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma
47. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver
48. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer
49. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
50. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
51. Effects of lycopene and Sho-saiko-to on hepatocarcinogenesis in a rat model of spontaneous liver cancer
52. Tumor angiogenesis: Therapeutic implications
53. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models
54. Endothelial cell marker expression in dysplastic lesions of the liver: An immunohistochemical study